NZ720273A - Preparations and methods for treating a gd2 positive cancer - Google Patents
Preparations and methods for treating a gd2 positive cancerInfo
- Publication number
- NZ720273A NZ720273A NZ720273A NZ72027314A NZ720273A NZ 720273 A NZ720273 A NZ 720273A NZ 720273 A NZ720273 A NZ 720273A NZ 72027314 A NZ72027314 A NZ 72027314A NZ 720273 A NZ720273 A NZ 720273A
- Authority
- NZ
- New Zealand
- Prior art keywords
- patient
- positive cancer
- preparations
- methods
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201314086696A | 2013-11-21 | 2013-11-21 | |
| EP13193953.0A EP2875827A1 (en) | 2013-11-21 | 2013-11-21 | Preparations and methods for treating a GD2 positive cancer |
| CA2834000A CA2834000A1 (en) | 2013-11-21 | 2013-11-21 | Method for treating a gd2 positive cancer |
| US14/182,776 US10294305B2 (en) | 2012-06-18 | 2014-02-18 | Method for treating a GD2 positive cancer |
| PCT/EP2014/075315 WO2015075194A1 (en) | 2013-11-21 | 2014-11-21 | Preparations and methods for treating a gd2 positive cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ720273A true NZ720273A (en) | 2022-02-25 |
Family
ID=53179006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ720273A NZ720273A (en) | 2013-11-21 | 2014-11-21 | Preparations and methods for treating a gd2 positive cancer |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10995147B2 (OSRAM) |
| EP (2) | EP3620173A1 (OSRAM) |
| JP (2) | JP6693873B2 (OSRAM) |
| AU (2) | AU2014351796B2 (OSRAM) |
| CA (1) | CA2930285A1 (OSRAM) |
| CY (1) | CY1122508T1 (OSRAM) |
| DK (1) | DK3071220T3 (OSRAM) |
| EA (1) | EA201691055A1 (OSRAM) |
| ES (1) | ES2768649T3 (OSRAM) |
| HR (1) | HRP20200128T1 (OSRAM) |
| HU (1) | HUE047920T2 (OSRAM) |
| LT (1) | LT3071220T (OSRAM) |
| NZ (1) | NZ720273A (OSRAM) |
| PL (1) | PL3071220T3 (OSRAM) |
| PT (1) | PT3071220T (OSRAM) |
| RS (1) | RS59817B1 (OSRAM) |
| SI (1) | SI3071220T1 (OSRAM) |
| SM (1) | SMT202000027T1 (OSRAM) |
| WO (1) | WO2015075194A1 (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| SI3071220T1 (sl) * | 2013-11-21 | 2020-03-31 | Apeiron Biologics Ag | Pripravki za zdravljenje GD2-pozitivnega raka |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| RU2663104C1 (ru) * | 2017-07-13 | 2018-08-01 | Общество с ограниченной ответственностью "Реал Таргет" | Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей |
| MX2020003201A (es) * | 2017-09-21 | 2020-08-13 | Umc Utrecht Holding Bv | Anticuerpo anti-gd2 para el tratamiento del neuroblastoma. |
| EP4175988A1 (en) * | 2020-07-06 | 2023-05-10 | EUSA Pharma (UK) Limited | Method for treating a gd2-positive cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| JP4731793B2 (ja) | 2000-12-28 | 2011-07-27 | アルセア テクノロジーズ インコーポレイテッド | 抗体全体またはそのフラグメントの結晶、ならびにこの結晶を作製および使用するための方法 |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| EP1572748B1 (en) | 2002-12-17 | 2010-06-23 | MERCK PATENT GmbH | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| DK1706428T3 (da) | 2004-01-22 | 2009-11-30 | Merck Patent Gmbh | Anti-cancer-antistoffer med reduceret komplementfiksering |
| BRPI0617688A2 (pt) | 2005-10-21 | 2011-06-07 | Hoffmann La Roche | método para expressão recombinante de um polipeptìdeo |
| EP1916257A1 (en) | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| US8278065B2 (en) | 2008-06-30 | 2012-10-02 | Morphotek, Inc. | Polynucleotides encoding anti-GD2 antibodies |
| US9315585B2 (en) | 2010-06-19 | 2016-04-19 | Memorial Sloan Kettering Cancer Center | Anti-GD2 antibodies |
| JP5623999B2 (ja) | 2010-08-31 | 2014-11-12 | パナソニック株式会社 | 電子装置 |
| SI2771364T1 (sl) | 2011-10-27 | 2019-10-30 | Genmab As | Produkcija heterodimernih proteinov |
| EP2861251A1 (en) | 2012-06-18 | 2015-04-22 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| SI3071220T1 (sl) * | 2013-11-21 | 2020-03-31 | Apeiron Biologics Ag | Pripravki za zdravljenje GD2-pozitivnega raka |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
-
2014
- 2014-11-21 SI SI201431460T patent/SI3071220T1/sl unknown
- 2014-11-21 SM SM20200027T patent/SMT202000027T1/it unknown
- 2014-11-21 LT LTEP14802642.0T patent/LT3071220T/lt unknown
- 2014-11-21 JP JP2016533187A patent/JP6693873B2/ja active Active
- 2014-11-21 EP EP19203951.9A patent/EP3620173A1/en not_active Withdrawn
- 2014-11-21 EA EA201691055A patent/EA201691055A1/ru unknown
- 2014-11-21 RS RS20200053A patent/RS59817B1/sr unknown
- 2014-11-21 DK DK14802642.0T patent/DK3071220T3/da active
- 2014-11-21 NZ NZ720273A patent/NZ720273A/en unknown
- 2014-11-21 PT PT148026420T patent/PT3071220T/pt unknown
- 2014-11-21 WO PCT/EP2014/075315 patent/WO2015075194A1/en not_active Ceased
- 2014-11-21 HU HUE14802642A patent/HUE047920T2/hu unknown
- 2014-11-21 AU AU2014351796A patent/AU2014351796B2/en active Active
- 2014-11-21 EP EP14802642.0A patent/EP3071220B1/en active Active
- 2014-11-21 ES ES14802642T patent/ES2768649T3/es active Active
- 2014-11-21 CA CA2930285A patent/CA2930285A1/en active Pending
- 2014-11-21 PL PL14802642T patent/PL3071220T3/pl unknown
- 2014-11-21 HR HRP20200128TT patent/HRP20200128T1/hr unknown
-
2019
- 2019-08-01 JP JP2019142173A patent/JP7139293B2/ja active Active
-
2020
- 2020-01-21 CY CY20201100048T patent/CY1122508T1/el unknown
- 2020-05-22 AU AU2020203346A patent/AU2020203346A1/en not_active Abandoned
- 2020-07-06 US US16/920,880 patent/US10995147B2/en active Active
-
2021
- 2021-03-03 US US17/190,792 patent/US11492412B2/en active Active
-
2023
- 2023-03-06 US US18/178,778 patent/US20240158530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20200332021A1 (en) | 2020-10-22 |
| ES2768649T3 (es) | 2020-06-23 |
| EA201691055A1 (ru) | 2016-11-30 |
| HRP20200128T1 (hr) | 2020-05-15 |
| JP7139293B2 (ja) | 2022-09-20 |
| DK3071220T3 (da) | 2020-02-10 |
| PT3071220T (pt) | 2020-02-03 |
| JP2016539122A (ja) | 2016-12-15 |
| JP2019218359A (ja) | 2019-12-26 |
| HUE047920T2 (hu) | 2020-05-28 |
| PL3071220T3 (pl) | 2020-05-18 |
| EP3071220B1 (en) | 2019-12-25 |
| WO2015075194A1 (en) | 2015-05-28 |
| CA2930285A1 (en) | 2015-05-28 |
| LT3071220T (lt) | 2020-02-25 |
| AU2014351796A1 (en) | 2016-05-26 |
| AU2020203346A1 (en) | 2020-06-11 |
| US11492412B2 (en) | 2022-11-08 |
| US10995147B2 (en) | 2021-05-04 |
| CY1122508T1 (el) | 2021-05-05 |
| SI3071220T1 (sl) | 2020-03-31 |
| EP3071220A1 (en) | 2016-09-28 |
| US20240158530A1 (en) | 2024-05-16 |
| AU2014351796B2 (en) | 2020-02-27 |
| HK1223039A1 (en) | 2017-07-21 |
| EP3620173A1 (en) | 2020-03-11 |
| AU2014351796A2 (en) | 2016-08-11 |
| RS59817B1 (sr) | 2020-02-28 |
| US20210221909A1 (en) | 2021-07-22 |
| SMT202000027T1 (it) | 2020-03-13 |
| JP6693873B2 (ja) | 2020-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX373301B (es) | Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos. | |
| MX377157B (es) | Preparación para usarse en el tratamiento de un cáncer positivo de gd2. | |
| SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX2020003719A (es) | Terapia que involucra anticuerpos contra claudina 18.2 para el tratamiento de cancer. | |
| NZ720736A (en) | Antibody drug conjugates (adcs) with kinesin spindel protein (ksp) | |
| MY188139A (en) | Sodium channel modulators for the treatment of pain | |
| NZ716473A (en) | Diagnosis and therapy of cancer involving cancer stem cells | |
| NZ720273A (en) | Preparations and methods for treating a gd2 positive cancer | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| SG10201903112WA (en) | Treatment of cancer using coenzyme q10 combination therapies | |
| MX2015014773A (es) | Tratamientos anti-cancer con anticuerpos anti-egfr que tienen una fucosilacion baja. | |
| MX2017015896A (es) | Agente anticancerigeno. | |
| WO2016051398A8 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| PH12020550462A1 (en) | Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same | |
| MX2017000366A (es) | Terapia de combinacion para el cancer. | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| TW201613578A (en) | Pharmaceutical combinations | |
| PH12016502352A1 (en) | Pharmaceutical composition | |
| MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
| HK1250626A1 (zh) | 借助塞里班土单抗的组合治疗 | |
| MX2015013091A (es) | Metodos mejorados de uso para secretoglobinas humanas recombinantes. | |
| PH12016500677A1 (en) | Specific anti-cd38 antibodies for treating human cancers | |
| MX2019003751A (es) | Proteina terapeutica. | |
| PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
| MX2020007222A (es) | Metodos para el tratamiento de afecciones inflamatorias de la piel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2023 BY CPA GLOBAL Effective date: 20221007 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2024 BY CPA GLOBAL Effective date: 20231006 |
|
| LECA | Licensee/mortgages/financial interest |
Name of requester: EUSA PHARMA Effective date: 20231123 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20241011 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 21 NOV 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20251010 |